From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
Efficacy Outcomes, % | TP1 | TP2Â¥ | |||
---|---|---|---|---|---|
SEC (N=83)^ | SEC (N=37) | PBO (N=37) | P-value | ||
JIA ACR | 30 | 90.4 | 89.2 | 64.9 | 0.014 |
50 | 86.7 | 78.4 | 62.2 | 0.152 | |
70 | 69.9 | 67.6 | 43.2 | 0.042 | |
90 | 39.8 | 51.4 | 40.5 | 0.431 | |
100 | 25.3 | 43.2 | 37.8 | 0.745 | |
Inactive disease# | 36.1 | 47.2 | 37.8 | 0.500 | |
JADAS-27, mean (SD) | 15.1 (7.2) | 14.6 (8.1) | 13.3 (5.8) | NA | |
Enthesitis count, mean change from BL (SD) | −1.8 (2.3) | −2.1 (2.0) | −1.9 (1.2) | NA |